Market growth for antibody-drug conjugates is strong in North America

Key market players are concentrating on various growth methods, such as getting product approval from regulatory agencies in order to increase their product portfolio in the market. This factor is likely to boost the market for antibody-drug conjugates. For example, in June 2019, the U.S. Food and Drug Administration (FDA) approved Policy, an antibody-drug combination developed by Roche Holding AG, a Swiss-based healthcare business. The policy is applied to people with advanced lymphoma. Antibody-drug conjugates are commonly utilized to treat chronic illnesses such as cancer. They are designed to solely destroy cancer cells.

1. LegoChem Biosciences and Takeda have jointly developed a drug-antibody conjugate in March 2019. This kind of conjugate is used in immuno-oncology

2. Lantern Pharma Announces an Agreement to Launch Antibody Drug Conjugate Program (ADC) by January 2021 to Target Solid Tumors and Blood Cancers

3. Novosep announces that their new €11 million bioconjugation facility has now been operational since February 2017

4. In August 2020, BOC Sciences, a chemical and pharmaceutical vendor, will introduce a new technology platform for antibody-drug conjugates.

5. Merck plans to invest €59 million to expand its manufacturing facilities for HPAPI and ADC in Madison, Wisconsin, USA.


Antibody-drug conjugation is the process of assembling antibodies and building them into complex structures known as antibodies. These structures are then integrated into small molecule cancer therapies. Antibodies are proteins that bind to and fight certain viruses or diseases. In concept, an antibody-drug conjugate is an assembly of antigens, or antibodies, that bind together in complex configurations to form the structure of disease-fighting molecules.


North America is expected to maintain a dominant position in the global antibody-drug conjugates market during the forecast period, owing to the expansion of key firms in various business strategies such as research and development to enhance global market presence. Seattle Genetics and Astellas Pharma, Inc., for example, announced in June 2019 the start date of the first cohort of pivotal phase 2 clinical trials called EV-201. It was discovered that the investigational medication enfortubmab vedotin, an antibody-drug combination, dramatically decreased tumor growth in the majority of patients.